Triple-Negative Breast Cancer: What’s New in Treatment and Research at MBC Patient Forum 2019

Nancy Lin, MD, discusses advances in research and treatment for patients with triple-negative metastatic breast cancer. Triple-negative breast cancer, which accounts for about 15% of all breast cancers, are a prime example of how quickly immunotherapy has become a standard part of treatment. Where patients were once treated with chemotherapy regimens, those whose tumors test positive for the PD-L1 checkpoint protein may now receive a checkpoint inhibitor along with chemotherapy at some point during their treatment.

Dr. Lin provides an overview of current research in triple-negative breast cancer, including trials for PARP inhibitors, immunotherapy, and antibody-drug conjugates. She shared results of a recent trial for patients whose tumors had worsened after standard chemotherapy. Treatment with the conjugate drug sacituzumab caused many of these participants’ tumors to shrink.

For more information about clinical trials for metastatic breast cancer, please visit

This information was presented at the EMBRACE Metastatic Breast Cancer Forum at Dana-Farber in October 2019.

EMBRACE (Ending Metastatic Breast Cancer for Everyone) is a Dana-Farber Cancer Institute program designed to offer metastatic breast cancer patients the best care possible by combining our expertise in clinical care and clinical research. As part of the program, our patients are offered a variety of supportive care resources and presented with emerging clinical trial opportunities in a personalized and ongoing basis. If you live a distance away, our care team can also collaborate with you and your local oncologist during your treatment. Near or far, we are here to provide active, continuous care to help you achieve the highest possible quality of life and make informed decisions about your care.

For more information about the EMBRACE Program, please visit

Category: News
About The Author